Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JSDZ | ISIN: FR0013357621 | Ticker-Symbol: 2WSA
Frankfurt
04.11.24
08:12 Uhr
47,700 Euro
-0,700
-1,45 %
Branche
IT-Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
WAVESTONE SA Chart 1 Jahr
5-Tage-Chart
WAVESTONE SA 5-Tage-Chart
RealtimeGeldBriefZeit
47,80048,90021:52
Actusnews Wire
343 Leser
Artikel bewerten:
(2)

WAVESTONE: Revenue target exceeded; +9% organic growth over the 2023/24 fiscal year - EBIT margin objective for 2023/24 confirmed

Revenue in €m
Unaudited consolidated data
2023/242023/24, excluding Q_PERIOR and Aspirant Consulting2022/23Change at constant scope* and on a constant forex basisTotal
change
Q1143.3143.3122.0+11%+17%
Q2133.4133.4115.1+14%+16%
Q3175.6150.9139.1+10%+ 26%
Q4248.8159.3156.0+4%+59%
12-month total701.1586.9532.3+9%+32%

* Excluding PEN Partnership, consolidated since August 1, 2022; Coeus Consulting, consolidated since October 1, 2022; Q_PERIOR consolidated since December 1, 2023; and Aspirant Consulting consolidated since February 1, 2024

Revenue growth of +59% in Q4 2023/24 - equivalent to +4% organic growth

In Q4 of the 2023/24 fiscal year (January 1 to March 31, 2024), Wavestone generated consolidated revenue of €248.8m, an increase of +59%, compared with Q4 of the previous fiscal year.

As a reminder, in addition to the UK-based consulting firms PEN Partnership and Coeus Consulting (consolidated respectively since August 1, 2022 and October 1, 2022), Wavestone has consolidated Q_PERIOR, a German consulting firm, since December 1, 2023 and Aspirant Consulting, a US-based consulting firm, since February 1, 2024.

At constant scope and exchange rates, revenue for Q4 2023/24 increased by +4%, showing, as expected, a slowdown in the firm's organic growth in the context of a hardening business environment. This figure takes into account the unfavorable working day impact over the last quarter of the fiscal year, standing at -1.5%[1].

Revenue of €586.9m excluding Q_PERIOR and Aspirant Consulting

At the end of the 2023/24 fiscal year, Wavestone's consolidated revenue stood at €701.1m, an increase of +32%, equivalent to +9% at constant scope and exchange rates (taking into account an unfavorable working day impact of -1.6%1). For the record, in 2023/24, Wavestone was targeting organic growth at least equal to that of the 2022/23 fiscal year (+7%).

Excluding Q_PERIOR and Aspirant Consulting, 12-month revenue reached €586.9m, exceeding the target of €580m.

Consultant utilization rate stable at 73% in 2023/24; sales price up by +1%

Due to an increased hesitancy in new projects at the start of the calendar year, and a less favorable business environment in the UK, the consultant utilization rate related to the scope excluding Q_PERIOR and Aspirant Consulting fell slightly in Q4, less than expected though. For the entire 2023/24 fiscal year, it stood at 73%; stable compared with the previous fiscal year.

The average daily rate on the same scope reached €898 in 2023/24 - an increase of +1% compared with the average sales price for the whole of the previous fiscal year (€890). At constant exchange rates, the average daily rate was €900 in 2023/24.

On the same scope still, with regard to business development, the order book fell slightly at 4.1 months of work at March 31, 2024, compared with 4.2 months at December 31, 2023.

Wavestone plans to deploy consolidated operating indicators (except order book) across the entire new firm from Q1 2024/25.

Q_PERIOR's business activity in line with plan

Q_PERIOR began the 2024 calendar year in a similar context to that of Wavestone. The resilient demand in the sectors of Insurance, Travel & Transportation and Energy helps limit the effects of a weaker economic environment in Germany.

In this regard, Q_PERIOR started the year with a consultant utilization rate in line with the last months of 2023 and the company's plan, but, like Wavestone, with a marked slowdown in terms of growth.

Caution maintained on recruitment; stable staff turnover

The staff turnover rate remained stable over the past quarter. At the end of March 2024, it stood at 14% on a rolling 12-month basis (a figure calculated on the scope excluding Q_PERIOR and Aspirant Consulting), compared with 16% over the whole of the previous fiscal year.

Faced with continuing uncertainty in the economic environment, Wavestone maintained its policy of a moderate pace of recruitment at the start of the 2024 calendar year. Over the whole of the 2023/24 fiscal year, the firm recruited about 800 new employees (excluding Q_PERIOR and Aspirant Consulting), compared with approximately 1,300 in the previous fiscal year.

As did Wavestone, Q_PERIOR continued a cautious recruitment policy at the start of the calendar year and its staff turnover rate remains low - at about 10%.

At March 31, 2024, Wavestone had 5,894 employees, including 1,422 from the combinations with Q_PERIOR and Aspirant Consulting. This compares with 4,406 at the end of the 2022/23 fiscal year.

Confirmation of the 2023/24 EBIT margin objective

Wavestone confirms its objective of an EBIT margin of about 15% for the 2023/24 fiscal year, excluding Q_PERIOR and Aspirant Consulting.

With regard to the fiscal year 2024/25, Wavestone is confident on its ability to generate growth of over 3%, while aiming for an EBIT margin of more than 13%, including Q_PERIOR and Aspirant Consulting on a full year basis, and excluding any new acquisition.

Wavestone will publish its 2024/25 annual results and financial objectives on June 3, 2024.

Next event: publication of the 2023/24 annual results, Monday, June 3, 2024, after Euronext market closing.

About Wavestone
Wavestone, a leading independent consultancy headquartered in France, and Q_PERIOR, a consulting leader in the Germany-Switzerland-Austria region, joined forces in 2023 to become the most trusted partner for critical transformations.
Drawing on more than 5,500 employees across Europe, North America and Asia, the firm combines seamlessly first-class sector expertise with a 360° transformation portfolio of high-value consulting services.
Wavestone is listed on Euronext Paris and recognized as a Great Place to Work®.

Wavestone
Pascal Imbert

CEO
Tel.: +33 (0)1 49 03 20 00
Justine Brosset
Financial Communication
Tel.: +33 (0)1 49 03 20 00
Actus
Mathieu Omnes

Investor and Analyst Relations
Tel.: +33 (0)1 53 67 36 92
Deborah Schwartz
Press relations
Tel.: +33 (0)1 53 67 36 35


[1] taking into account the geographical distribution of Wavestone's workforce

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: mWppY5Vok26Wym5pkp5tZmmZb2dhxWeXZWicyGlsYp+dmm9lxmpob5ydZnFmmWhm
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-85430-2024-03-402-ca-communique-ca-t4-2023-2024-en.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.